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Presentation of case
Dr. D. Schiller: Since age 18 the patient had suffered
from mild psoriasis that was treated with intermit-
tent courses of topical corticosteroids. For the past
5 years he had complained of pain in his finger joints
aggravated by manual work. The patient worked in an
office and denied morning stiffness, back pain, repet-
itive strain injury related to leisure activities, enthe-
siopathy, gout or inflammation of the eyes. His family
history was unrevealing. For the past 3 years he had
taken lisinopril and hydrochlorthiazide for arterial hy-
pertension.
An ileocolonoscopy due to diarrhea 5 months prior
to admission showed diffuse mucosal erythema of the
descending and sigmoid colon. Biopsies showed
nonspecific inflammation with slightly increased
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eosinophils in the lamina propria. Esophagogas-
troduodenoscopy with gastric and duodenal biopsies
yielded normal results; the hydrogen breath test sug-
gested lactose intolerance. His diarrhea resolved with
a lactose-poor diet and 5-aminosalicylic acid (5-ASA,
3 g per day for 3 months).
After an exacerbation of his psoriasis had persisted
for 4 weeks he was admitted with pustules and pro-
gressive diffuse erythrodermia covering about 80% of
his body. The pustules were round with desquamating
margins. On physical examination he was afebrile; his
weight was 83 kg and height 178 cm. The finger- and
toenails appeared normal. Several finger joints and
the metacarpophalangeal (MCP) joints of both index
and middle fingers were swollen and indurated with-
out hyperthermia or erythema.
Routine laboratory tests, including a complete
blood count, liver and renal function tests, erythrocyte
sedimentation rate, C-reactive protein (CRP) as well
as antinuclear antibodies (ANA), anti-cyclic citrulli-
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Fig. 1 Radiographyof the lefthandwithsubchondralcystsand
osteophytes in the2ndand3rdMCP joints (arrows), andover-
hanging andhook-like radial osteophyte in the3rdmetacarpal
head (arrow head). Themarginsof these joints are irregular but
the joint spaceswereunremarkable. Thesefindingswere the
same for bothhands
nated peptide (anti-CCP) antibodies, immunoglobu-
lin (Ig) G, IgA, IgM and anti-tissue-transglutaminase
antibodies were normal or negative. Chest radiogra-
phy and abdominal ultrasound were unremarkable.
Plain radiographs of the hands showed irregular mar-
gins of the 2nd and 3rd MCP joints bilaterally with
some small subchondral cysts and osteophytes on
the radial side. Cystic changes were also seen in the
carpal bones bilaterally, most pronounced in the os
triquetrum and lunatum.
A diagnostic procedure was performed.
Dr. C. Langner: Histological examination of the
colon biopsies mentioned in the protocol revealed
active inflammation of the lamina propria with neu-
trophil cryptitis and mild eosinophilia. Since these
histopathological features are not very specific and
can be found within a wide spectrum of diseases, his-
tology does not provide a clear clue for an underlying
disease.
Dr. H. Schoellnast: Radiography of the hands showed
a remarkably symmetric pattern with subchondral
cysts and osteophytes in the 2nd and 3rd MCP joints
of both hands. There were hook-shaped radial os-
teophytes, most pronounced in the metacarpal head.
Bilaterally, the margins of these joints were irregular;
the joint spaces were unremarkable. Except for some
further small subchondral cystic lesions in single
carpal bones that were most pronounced in the tri-
quetum and lunatum, radiography was unremarkable
(Fig. 1).
Differential diagnosis
Dr. W. Graninger: The patient had a medical history
of psoriasis with mild course so far and arthralgia of
the finger joints, but required hospitalization when
he presented with this acute exacerbation of his pso-
riasis featuring round pustular rash, desquamation,
and progressive diffuse erythrodermia affecting about
80% of his skin, and joint pain in the hand (several
finger joints and the 2nd and 3rd MCP joints of both
hands were swollen and indurated but without ery-
thema and hyperthermia). At first glance, these find-
ings suggest psoriatic arthritis, which is a symmet-
ric, progressive, chronic inflammatory joint disorder
with heterogeneous clinical features that may include
plaque psoriasis, joint inflammation, enthesitis (in-
flammation at the sites where tendons or ligaments
insert into the bone), dactylitis (diffuse swelling of the
fingers and toes), and abnormal bone turnover. Psori-
atic arthritis affects up to 0.5% of the population with
equal prevalence in males and females [1]. Methotrex-
ate and infliximab are standard medications for psori-
atic arthritis. In this patient, psoriatic arthritis is, how-
ever, questionable because (1) there are no histologi-
cal findings confirming the diagnosis of plaque psori-
asis and diffuse pustulous erythrodermia, (2) there is
no evidence from laboratory data (normal erythrocyte
sedimentation rate and normal CRP levels are atypical
for psoriatic arthritis when psoriasis affects 80% of the
skin; however, cases of erythrodermia due to Sézary
syndrome and seronegative polyarthritis with normal
laboratory results have been described [2]), and (3)
the patient’s finger- and toenails were unremarkable
but would be expected to show typical changes with
psoriatic arthritis. For the right diagnosis we, there-
fore, have to look at additional facts. Five months
prior to admission due to exacerbation of psoriasis
and arthralgia of the finger joints, the patient had
suffered from diarrhea and was diagnosed with lac-
tose intolerance and acute colitis with eosinophils in
the lamina propria. Eosinophilic colitis is a nonspe-
cific diagnosis that can be found in a wide spectrum
of diseases. In this case, medical treatment with 3 g
5-ASA per day for 3 months successfully resolved the
gastrointestinal symptoms. Unfortunately, a follow-
up colonic biopsy is not available, so it is not clear
whether the mucosa recovered under this treatment.
Adverse drug reactions with 5-ASA [3] are rare, and
it is unlikely that our patient’s dermatological symp-
toms represented an adverse drug reaction because
the acute exacerbation of psoriasis and erythroder-
mia did not develop until 2 months after 5-ASA was
discontinued.
Focusing on the arthralgia of finger joints, it has
to be emphasized that the 2nd and 3rd MCP joints
on both hands were mainly affected. This is a very
specific finding because osteoarthritis of the hand
usually affects distal and proximal, interphalangeal
and basal joints of the first ray, but not MCP joints.
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Table 1 Featuresof hemochromatosis arthropathyandother common joint conditions [11, 12]
Hemochromatosis Osteoarthritis Rheumatoid arthritis CPPD crystal deposition
disease
Age of onset <50 years >50 years >45 yearsa Usually >60 years
Chondrocalcinosis Common Rare Rare Very common
MCP involvement Very common Rare Very common Common
Signs of synovitis Occasional Rare Very common Episodic
Marginal erosions Very rare Very rare Common Very rare
MCP metacarpophalangeal, CPPD calcium pyrophosphate dehydrate
aIncidence appears to increase in men after age 45; in women incidence increases to a plateau and then appears to decline after age 75–80
Further, the MCP joints of both index and middle
fingers were described as swollen and indurated but
without erythema and hyperthermia, which might be
due to synovitis. Sonography of the hands would be
helpful here and would allow differentiation between
degenerative changes of the joints, psoriatic arthritis,
perisynovitis, and other rheumatological diseases [4].
In addition to subchondral cysts and osteophytes,
radiography also revealed irregular margins of the
2nd and 3rd MCP joints of both hands. These man-
ifestations in the MCP joints are specifically found
in Dietrich’s disease, an avascular necrosis. Causes
for avascular necrosis include trauma (fracture or
dislocation), caisson disease, hemoglobinopathies
such as sickle cell disease, pregnancy, radiotherapy,
connective tissue disorders, renal transplantation,
corticosteroid excess (both endogenous and exoge-
nous), pancreatitis, gout, Gaucher’sdisease, and alco-
hol abuse [5]. However, since none of these causes
seem to apply to our patient, I would exclude Diet-
rich’s disease as a differential diagnosis. Subchondral
cysts as found here are typical for degenerative joint
disease, rheumatoid arthritis, calcium pyrophosphate
dihydrate (CPPD) crystal deposition disease, avascu-
lar necrosis, hemophilia, sickle cell disease, multiple
myeloma, amyloidosis, hemochromatosis, Wilson’s
disease, and hyperparathyroidism [6]. Since routine
laboratory tests, including complete blood count, liver
and renal function tests, erythrocyte sedimentation
rate, CRP, ANA, anti-CCP antibodies, IgG, IgA, IgM,
and anti-tissue-transglutaminase antibodies were
normal or negative, most of those diseases can be
excluded. However, the radiologic constellation with
characteristic changes, subchondral cysts and osteo-
phytes primarily affecting the 2nd and 3rd MCP joints
of both hands is a typical finding in hemochromato-
sis. This is an iron metabolism disorder characterized
by increased intestinal iron absorption and progres-
sive deposition in organs and tissues resulting in
injury and functional impairment, particularly in the
liver, pancreas, heart, joints, and pituitary [7]. Lab-
oratory findings include increased ferritin levels and
enhanced transferrin saturation. Schumacher first
recognized the relationship between hemochromato-
sis and arthritis in 1964 [8]. Joint pain is present
in about 30% of affected patients and is sometimes
reported as the first symptom. Typically, the 2nd
and 3rd MCP joints are involved but virtually any
joint can be affected with signs and symptoms of
osteoarthritis [9, 10]. Moreover, hook osteophytes
along the radial aspect of the distal metacarpals are
frequently found in arthropathy due to hemochro-
matosis. These hook osteophytes can also be seen in
CPPD crystal deposition disease but are more preva-
lent in hemochromatosis. Generally, crystals are not
associated with hemochromatosis arthropathy, but
some patients may present with apatite and CPPD
crystals, in which case arthritis mimics pseudogout
(Table 1) [11, 12]. To further differentiate between
hemochromatosis and CPPD crystal deposition dis-
ease, the following has to be considered: Both diseases
involve the radiocarpal and midcarpal compartments
of the wrist with diffuse joint space narrowing and
intraarticular and periarticular calcifications, which
are not seen with osteoarthritis. What helps to differ-
entiate between hemochromatosis and CPPD crystal
deposition disease is the joint space. In hemochro-
matosis arthropathy there is uniform loss of joint
space at all the MCP joints including those of the ring
and little fingers, while in CPPD crystal deposition
disease there is narrowing predominantly of the index
and the middle finger MCP joints [13]. Hook osteo-
phytes may also be present on radiographs in cases
of erosive arthropathy, but in erosive arthropathy dis-
tal interphalangeal joints are affected and clinically,
these hook osteophytes have a distinct brown, wart-
like appearance [14]. Since the pathological changes
in this patient’s finger joints and his erythrodermia
are not features of erosive arthropathy, this diagnosis
can be ruled out.
Due to the clinical presentation, sarcoidosis or os-
teitis cystica multiplex (Jüngling’s disease), a slowly
progressive form of osteitis with cystic changes ex-
tending into surrounding soft tissue in the acral re-
gions (fingers, toes, nose) might also be considered as
diagnosis here, if it were not for our patient’s normal
chest radiographs.
Taken together, we have three important find-
ings in this case: cystic arthropathy in the 2nd and
3rd MCP joints, pustulous psoriasis affecting 80%
of the skin, and eosinophilic colitis. The radiolog-
ical findings strongly suggest arthropathy associ-
ated with hemochromatosis. Further laboratory data
such as ferritin, transferrin saturation, and search
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for hemochromatosis gene mutations are needed to
confirm this diagnosis. Moreover, I would suggest
performing a skin biopsy to provide more informa-
tion on his skin disease with pustulous psoriasis and
erythrodermia.
Dr. W. Graninger’s diagnosis
Arthropathy due to hemochromatosis.
Discussion of case
Dr. G.J. Krejs: Our patient did indeed suffer from
hemochromatosis-associated arthropathy. The radi-
ologist (J. F.) gave the first hint pointing toward the
right diagnosis by noting the characteristic changes
in the 2nd and 3rd MCP joints of both hands. Dr.
Schoellnast will explain these remarkable radiological
features of hemochromatosis arthropathy in detail.
Dr. H. Schoellnast: Radiological features of hemo-
chromatosis arthropathy of the hands are usually
seen bilaterally and include joint space narrowing,
cyst formation, and osteophytes in the 2nd and 3rd
MCP joints and less frequently in the 4th and 5th
MCP joints as well. Typical findings in hemochro-
matosis are hook- or beak-shaped osteophytes along
the radial aspect of the 2nd and 3rd metacarpal heads,
features that are not seen with osteoarthritis. MCP
joint manifestations are common in hemochromato-
sis although other joints such as the wrists, knees,
hips, shoulders, and ankles may also be affected
[9, 10]. In hemochromatosis arthropathy, joints are
not usually affected by the degenerative or erosive
changes that are typical for other polyarthropathies
of the hand including psoriatic arthritis. The location
of the pathological changes occurring with various
arthropathies is characteristic for particular diseases.
While hemochromatosis arthropathy typically affects
the 2nd and 3rd MCP joints, other arthropathies
typically affect distal interphalangeal and proximal
interphalangeal joints and the basal joint of the first
ray, but not the MCP joints. In this patient, the
margins of the affected MCP joints were slightly ir-
regular in both hands but there were no signs of
degenerative or erosive disease. The joint spaces were
unremarkable, though they can also show character-
istic changes, i. e. uniform loss of joint space in all the
MCP joints (2nd–5th). This feature may also help to
differentiate between hemochromatosis arthropathy
and other pathological changes such as CPPD crystal
deposition disease, where MCP joint space narrowing
is less prevalent and predominantly affects the 2nd
and 3rd MCP joints. In hemochromatosis arthropa-
thy the 4th and 5th MCP joints are also more often
narrowed [13, 15]. Since their features substantially
overlap (including chondrocalcinosis, radiographic
appearance, and to a large degree distribution of af-
fected joints), it may be very difficult to differentiate
between hemochromatosis arthropathy and CPPD
crystal deposition disease. Radiologically, CPPD crys-
tal deposition disease in the wrist is more likely to
cause scapholunate dissociation, which is a loss of the
normal anatomical articulation of the scaphoid with
the lunate, manifesting as a malalignment of these
bones on an anteroposterior projection [13, 15].
Dr. D. Schiller: In this patient the radiologist sus-
pected the diagnosis of hemochromatosis arthropa-
thy, which could be confirmed by the following pa-
rameters: serum iron 307 µg/dl (normal: 37–170 µg/
dl), transferrin saturation 100% (normal: 20–60%),
serum ferritin 2080 ng/ml (normal: 11–264 ng/ml).
HFE gene analysis showed a homozygous C282Y mu-
tation in the HFE gene. Hemochromatosis is a ge-
netic disorder of iron metabolism leading to increased
enteric absorption of iron and progressive total body
iron overload. Excessive iron stores and deposition of
hemosiderin can cause tissue damage and dysfunc-
tion in a number of organ systems [16]. The diag-
nosis of hemochromatosis is sometimes delayed be-
cause the symptoms are nonspecific and overlap with
those of other conditions. Joint manifestations are
common and as in our patient may lead to the diag-
nosis of hemochromatosis. However, as discussed by
Dr. Graninger, it has to be considered that joint find-
ings in hemochromatosis may mimic those seen in
other common rheumatologic conditions such as os-
teoarthritis and rheumatoid arthritis. Chondrochalci-
nosis or CPPD crystal deposition disease (pseudogout)
is frequently found in patients with hemochromato-
sis and may be the first manifestation. Routine ge-
netic screening of these patients for hemochromatosis
has been shown to be cost effective because it allows
early identification and treatment [17]. The clinical
features of hemochromatosis result from damage to
various organs due to iron overload and appear ear-
lier in affected men than in women [18, 19]. Since
diagnostic tools have improved, the classic presenta-
tion with cirrhosis, diabetes mellitus, and bronze skin
is rarely seen today; the most common initial symp-
toms are fatigue, malaise, and joint pain [18]. Hep-
atic iron overload leads progressively to fibrosis and
cirrhosis with ultimately an increased risk of hepato-
cellular carcinoma. Deposition of iron in islet cells of
the pancreas may result in diabetes mellitus, while
cardiac iron deposition may cause cardiomyopathy
with arrhythmia and congestive heart failure. Iron
overload in the pituitary gland can lead to hypogo-
nadotropic hypogonadism, hypothyroidism, or pan-
hypopituitarism. Hypopituitarism is characteristic for
juvenile hemochromatosis (hemochromatosis type 2)
and is often its first manifestation [20]. Moreover, pa-
tients with iron overload, including those with hered-
itary hemochromatosis, are at risk for a number of
bacterial infections (e. g., Yersinia enterocolitica, Liste-
ria monocytogenes, Vibrio vulnificus) [21–23].
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After our patient was diagnosed with hemochro-
matosis, therapeutic phlebotomy was initiated. Phle-
botomy is the mainstay of treatment, both for ini-
tial depletion of excess iron stores and for subse-
quent maintenance of normal total body iron. There
are no standardized guidelines but the efficacy of
phlebotomy has been reported with an induction
regime of removal of 500 ml of whole blood weekly
(i. e. 200–250 mg iron) until the hematocrit falls
2–4% below baseline and ferritin levels normalize
to within 25–50 µg/l. Lifelong maintenance phle-
botomy involves removal of 500 ml of whole blood
every 2–4 months in men or every 3–12 months in
women before menopause. This therapy usually al-
lows maintenance of the serum ferritin level within
the lower normal range. If iron parameters increase,
suggesting inadequate iron removal, the frequency
of phlebotomy has to be adapted. In the absence of
contraindications, phlebotomized blood can be used
for blood donation [20].
Dr. G.J. Krejs: Progressive hemochromatosis is po-
tentially fatal; before the introduction of phlebotomy
therapy in the 1950s, mean survival after diagnosis
was only 1.5 years. Today, decompensated liver cir-
rhosis and hepatocellular carcinoma represent the
main causes of hemochromatosis-related mortality,
mostly due to delayed diagnosis [24, 25]. Phlebotomy
is a highly effective therapeutic approach in mild to
moderate hemochromatosis and adequately treated
patients have a normal life expectancy [26]. Especially
when the disease is mild, some clinical features may
be reversed with adequate therapy. However, unlike
the other organopathies observed with hemochro-
matosis, arthritis does not regress with treatment [27,
28] and it is suggested that severity of hemochromato-
sis arthropathy correlates with iron stores [29]. Iron
is known to catalyze oxidative reactions with subse-
quent formation of reactive oxygen species that can
cause inflammation and tissue damage. Moreover,
iron stimulates DNA synthesis in synovial cells with
an additive effect on cell proliferation, together with
cytokines such as IL-1ß and TNF-α [30]. This suggests
that iron has a pivotal role in modulating the activity
of arthropathies and may also be a relevant factor in
rheumatological diseases [31].
As mentioned, hemochromatosis is also associated
with an enhanced risk for various infectious diseases
because iron is an essential growth factor for many
bacteria and increases bacterial virulence [32, 33].
Moreover, data indicate that iron has a significant
unfavorable influence on the human gut microbiota
and so may indirectly trigger intestinal inflamma-
tion in patients with hemochromatosis [32, 34]. This
might have been a relevant contributing factor to
our patient’s nonspecific colonic inflammation. We
think that he had some form of infectious colitis
that cleared. Recently, clinical observations highlight
the relationship between iron and Helicobacter py-
lori infection. This infection is frequently associated
with refractory iron deficiency anemia that responds
favorably to Helicobacter pylori eradication [35, 36].
Helicobacter pylori can contribute to low iron status
by different mechanisms. These include bacterial
uptake of dietary and host-derived (lactoferrin, satu-
rated transferrin, hemoglobin) iron, which increases
virulence and may decrease human iron status. In-
creased virulence may accelerate development of
atrophic gastritis, resulting in hypo- or achlorhydria
and reduced secretion of vitamin C from the gastric
epithelium, which also impairs iron uptake. Further,
low iron status contributes to induction of gastric
hepcidin, thus, promoting development of peptic
ulcer [37, 38].
The influence of gastric acid secretion on iron ab-
sorption is also emphasized by the increased notion
that achlorhydria in atrophic gastritis may be the sole
cause of iron deficiency anemia [39, 40]. Therapeutic
hypochlorhydria caused by proton pump inhibitors
may thus reduce the frequency of phlebotomy in pa-
tients with hemochromatosis [41].
Dr. D. Schiller: The potential gain of information
from a liver biopsy was discussed with the patient and
he agreed to a blind liver biopsy, which was carried out
without complications.
Dr. C. Langner: Liver biopsy is very informative in
selected patients with hemochromatosis but is not
standard since it usually will not provide further infor-
mation (cirrhosis is not likely to be present in patients
with a serum ferritin level lower than 1000 ng/ml) or
prompt a change in therapy [42]. Since ferritin ex-
ceeded 1000 ng/ml in this case, biopsy was recom-
mended to evaluate whether and/or to what extent
the liver had already been affected by iron overload.
The liver biopsy showed mild enlargement of the
portal fields with occasional porto-portal bridging,
but no cirrhosis. There was mild necroinflammatory
activity within the lobular parenchyma as well as mild
steatosis. Iron stains showed marked accumulation
of iron in hepatocytes and occasional macrophages
within the portal fields (Fig. 2).
Dr. R. Stauber: Generally, besides liver biopsy, Fi-
broscan™ could also be applied to grade fibrosis due
to hepatic iron overload in hemochromatosis. Since
this method is not well standardized for this disease
it can only provide limited information on the effects,
if any, of iron overload. Thus, in some patients with
hemochromatosis, liver biopsy is necessary to obtain
further diagnostic and prognostic information.
Hemochromatosis is an inherited disorder of iron
metabolism leaving the patients unable to effectively
regulate their iron absorption and so resulting in pro-
gressive accumulation of iron. Several different types
of the disease have so far been described. In these
individuals absorption of both inorganic and heme
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blue staining identifies the
pigment asaccumulationof
iron, i. e. hemosiderin (d)
iron is increased [43] because basolateral efflux of
iron from the enterocytes is inappropriately regulated
[44, 45]; most importantly hepcidin levels are very low
in patients with hemochromatosis type 1 (mutation
of the HFE gene, MIM #235200) [46]. In a normal in-
dividual an increase in body iron levels would lead to
increased hepcidin expression and this in turn would
decrease iron absorption by reducing basolateral ef-
flux. Such an increase in hepcidin does not occur
in patients with HFE-associated hemochromatosis,
so that their iron absorption continues in the face of
body iron overload. Mutations of HFE, hemojuvenil,
hepcidin, transferrin receptor 2 (TfR2), Ireg1, trans-
ferrin, ceruloplasmin and ferritin all lead to some
form of iron overload [47]. Of these, mutations in
the HFE gene located on chromosome 6 are by far
the most common [48] and >80% of patients with
hemochromatosis are homozygous for HFE mutation
C282Y (rs1800562, G845A) [49, 50]. HFE-associated
hemochromatosis, the most common type in adults,
is regarded as the most prevalent autosomally in-
herited genetic disease of Caucasians with an allele
frequency of C282Y of 6.2% and a homozygosity
frequency of 0.38% in a pool of 127,613 individu-
als. However, there is considerable variation across
Europe with allele frequencies of >10% in Ireland
and 0–3% in Mediterranean regions [27]. In the US,
homozygosity for the C282Y mutation accounts for
most cases of hemochromatosis followed by H63D
and S65C mutations. Heterozygosity of C282Y and
H63D is seen only infrequently. Penetrance of C282Y
is, however, low. A population-based study revealed
mildly elevated liver enzymes or liver disease in <10%
of C282Y homozygotes and the estimated prevalence
of clinical hemochromatosis was as low as 1% [51].
Other studies reported liver disease in up to 16%
of C282Y homozygotes [52]. In addition to the par-
ticular genetic variant, penetrance of the mutation
and environmental factors such as diet, alcohol con-
sumption, coexisting chronic viral hepatitis, and host
factors such as gender, age, and obesity may in-
fluence the course of hemochromatosis-associated
fibrosis and cirrhosis [27, 53]. Patients with HFE-as-
sociated hemochromatosis absorb excessive amounts
of iron from birth, which entails excessive iron accu-
mulation in parenchymal cells of the liver, heart, and
endocrine organs [53]. While a normal adult male
may have 3.5 g of storage iron in his body, patients
with hemochromatosis may reach 20–30 g or more
before clinical symptoms occur [18]. In my experi-
ence patients typically first present around age 50
due to hepatic symptoms; about 1/3 of affected pa-
tients have joint manifestations and are first seen by
rheumatologists. Sometimes chondrocalcinosis and
subsequent profound joint destruction of the knees,
hips, or shoulders may have already necessitated joint
replacement before the diagnosis of hemochromato-
sis. Hemochromatosis type 2, also defined as juvenile
hemochromatosis, is divided into type 2A (muta-
tion of the hemojuvenile gene, HJV, MIM #602390)
and type 2B (mutation of the hepcidin antimicrobial
peptide gene, HAMP, MIM #613313). Mutations in
the transferrin receptor 2 (TFR2) gene were iden-
tified as a cause of hemochromatosis type 3 (MIM
#604250) [54]. Hemochromatosis types 4 and 5 are
associated with mutations of the ferroportin (Ireg 1)
gene (SLC40A1, MIM #606069) and mutations of the
H ferritin gene (FTH1, MIM #615517), respectively
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[55]. Genes associated with iron metabolism repre-
sent obvious candidates for mutations that lead to
iron overload and disease phenotype in hemochro-
matosis. Further investigations will determine the
role of each of these genes and their mutations and
also of duodenal cytochrome b (DCYTB, CYBYRD1)
and others in iron accumulation [47].
Dr. G.J. Krejs: This case clearly shows that diagnosis
of hemochromatosis can sometimes be difficult and is
often delayed for decades because of silent iron depo-
sition without symptoms. Since the clinical features
are nonspecific and the symptoms of hemochromato-
sis arthropathy overlap with those of other rheumato-
logic conditions, diagnosis is difficult even in symp-
tomatic patients. Currently, our patient has regular
therapeutic phlebotomy and he will surely also be
screened regularly for hepatocellular carcinoma.
Dr. W. Graninger: In this case a history of psoriasis
made it difficult to relate the joint symptoms to their
true cause, hemochromatosis. Joint symptomsmay be
the first manifestation of hemochromatosis, especially
when it is HFE-associated. Although it is sometimes
difficult, there are both clinical and radiographic clues
to differentiate between hemochromatosis arthropa-
thy and other rheumatologic diseases. Rheumatol-
ogists should be aware of the characteristic clinical
features and symptoms, and the typical radiologic
findings in hemochromatosis arthropathy to correctly
identify hemochromatosis patients as early as possi-
ble, thus, ensuring adequate treatment.
Final diagnosis
Hemochromatosis arthropathy.
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